Cargando…

Combination immunotherapy with interleukin‐2 surface‐modified tumor cell vaccine and programmed death receptor‐1 blockade against renal cell carcinoma

Immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma. Streptavidin‐interleukin‐2 (SA‐IL‐2) surface‐modified tumor cell vaccine developed through our protein‐anchor technology could induce specific antitumor T‐cell responses, but this immunotherapy cannot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xinji, Shi, Xiaojun, Li, Jinlong, Hu, Zhiming, Gao, Jimin, Wu, Shihao, Long, Zhaolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317916/ https://www.ncbi.nlm.nih.gov/pubmed/30343514 http://dx.doi.org/10.1111/cas.13842

Ejemplares similares

PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine
por: Zhang, Xinji, et al.
Publicado: (2018)

Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer
por: Zhang, Xinji, et al.
Publicado: (2021)

Norcantharidin enhances antitumor immunity of GM‐CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells
por: Mo, Lijun, et al.
Publicado: (2018)

LncARSR sponges miR-129-5p to promote proliferation and metastasis of bladder cancer cells through increasing SOX4 expression
por: Liao, Chunxian, et al.
Publicado: (2020)

Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer
por: Zhang, Xinji, et al.
Publicado: (2020)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
por: Qi, Yihang, et al.
Publicado: (2021)

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
por: Zhang, Jiulong, et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Role of renal tubular programed cell death in diabetic kidney disease
por: Zhou, Xiaojun, et al.
Publicado: (2022)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma
por: Yu, Nathan Y, et al.
Publicado: (2018)

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
por: McCaughan, Georgia J. B., et al.
Publicado: (2016)

Newcastle disease virus co‐expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
por: Xu, Xiaojing, et al.
Publicado: (2018)

Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy
por: Chen, Meng, et al.
Publicado: (2023)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
por: Li, Le, et al.
Publicado: (2023)

Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies
por: Waibl Polania, Jessica, et al.
Publicado: (2021)

Immunotherapies: The Blockade of Inhibitory Signals
por: Wu, Yan-Ling, et al.
Publicado: (2012)

Interleukin 15 in Cell-Based Cancer Immunotherapy
por: Zhou, Yang, et al.
Publicado: (2022)

Interleukin‐2 Prevents Programmed Cell Death in Adult T‐Cell Leukemia Cells
por: Tsuda, Hiroyuki, et al.
Publicado: (1993)

Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
por: Adachi, Takaomi, et al.
Publicado: (2013)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
por: Guram, Kripa, et al.
Publicado: (2019)

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors
por: Jiang, Chang, et al.
Publicado: (2018)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
por: Versteven, Maarten, et al.
Publicado: (2018)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018)

Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockade
por: Marsh, Rachel L., et al.
Publicado: (2020)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer’s Disease Mouse Models
por: Zou, Yulian, et al.
Publicado: (2021)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
por: Wang, Zhenqing, et al.
Publicado: (2021)

Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade
por: Li, Qiuyi, et al.
Publicado: (2022)

Transformable prodrug nanoplatform via tumor microenvironment modulation and immune checkpoint blockade potentiates immunogenic cell death mediated cancer immunotherapy
por: Yang, Weijing, et al.
Publicado: (2023)

Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma
por: Jiang, Silin, et al.
Publicado: (2023)

Blockade of maitotoxin-induced oncotic cell death reveals zeiosis
por: Estacion, Mark, et al.
Publicado: (2002)

Immunotherapy for Renal Cell Carcinoma
por: Itsumi, Momoe, et al.
Publicado: (2010)

Immunology of Cell Death in Cancer Immunotherapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2021)

Immunogenic cell death in cancer immunotherapy
por: Choi, Minji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_43r07nrf81fgnel0tmsegril1k